Table 2.
Characteristics of patients screened: not enrolled by site choice or patient choice.
| Total | Total | Enrolled | lneligible | Not enrolled | |||
|---|---|---|---|---|---|---|---|
|
|
|
|
|
||||
| By site choice | By patient choice | ||||||
|
|
|
||||||
| No. (Col %) 7452 | No. (Row %) 3868 (51.9) | No. (Row %) 1469 (19.7) | No. (Row %) (Col %) 358 (4.8) | OR (95% Cl) − (−) | No. (Row %) (Col %) 1757 (23.6) | OR (95% Cl) − (−) | |
|
| |||||||
| Sex | |||||||
| Male | 4046 (54.3) | 2119 (52.4) | 791 (19.6) | 225 (5.6) (62.8) | 1.0 (−) | 911 (22.5) (51.8) | 1.0 (−) |
| Female | 3406 (45.7) | 1749 (51.4) | 678 (19.9) | 133 (3.9) (37.2) | 0.72 (0.57–0.90)b | 846 (24.8) (48.2) | 1.13 ( 1.01–1.26)b |
| Age group (years)a | |||||||
| 2–17 | 757 (10.2) | 480 (63.4) | 101 (13.3) | 29 (3.8) (8.1) | 1.0 (−) | 147 (19.4) (8.4) | 1.0 (−) |
| 18–35 | 2878 (38.6) | 1567 (54.4) | 492 (17.1) | 140 (4.9) (39.1) | 1.48 (0.98–2.23) | 679 (23.6) (38.6) | 1.42(1.15–1.74)b |
| ≥36 | 3816 (51.2) | 1821 (47.7) | 876 (23.0) | 189 (5.0) (52.8) | 1.72 (I.l5–2.57)b | 930 (24.4) (52.9) | 1.67 ( 1.36–2.04)b |
| Unknown | 1 (0) | − (−) | − (−) | − (−) (−) | − (−) | 1 (100) (0.1) | − (−) |
| Birthplacec | |||||||
| Canada and United States | 2368 (31.8) | 1391 (58.7) | 383 (16.2) | 125 (5.3) (34.9) | 1.0 (−) | 469 (19.8) (26.7) | 1.0 (−) |
| Africa | 261 (3.5) | 104 (39.8) | 50 (19.2) | 10 (3.8) (2.8) | 1.07 (0.55–2.10) | 97 (37.2) (5.5) | 2.77 (2.06–3.72)b |
| Americas—other | 2824 (37.9) | 1758 (62.3) | 358 (12.7) | 120 (4.2) (33.5) | 0.76 (0.59–0.99)b | 588 (20.8) (33.5) | 0.99 (0.86–1.14) |
| Eastern Mediterranean | 153 (2.1) | 66 (43.1) | 27 (17.6) | 29 (19.0) (8.1) | 4.89 (3.05–7.85)b | 31 (20.3) (1.8) | 1.39 (0.9–2.16) |
| Europe | 282 (3.8) | 151 (53.5) | 56 (19.9) | 8 (2.8) (2.2) | 0.59 (0.28–1.23) | 67 (23.8) (3.8) | 1.32 (0.97–1.79) |
| South-East Asia | 207 (2.8) | 92 (44.4) | 41 (19.8) | 7 (3.4) (2.0) | 0.85 (0.38–1.87) | 67 (32.4) (3.8) | 2.16 (1.55–3.01)b |
| Western Pacific | 1008 (13.5) | 303 (30.1) | 418 (41.5) | 34 (3.4) (9.5) | 1.25 (0.84–1.86) | 253 (25.1) (14.4) | 2.48 (2.03–3.02)b |
| Non-WHO region | 3 (0) | 2 (66.7) | − (−) | − (−) (−) | − (−) | 1 (33.3) (0.1) | − (−) |
| Unknown | 346 (4.6) | 1 (0.3) | 136 (39.3) | 25 (7.2) (7.0) | − (−) | 184 (53.2) (10.5) | − (−) |
| Screening countryd | |||||||
| United States | 621 1 (83.3) | 3164 (50.9) | 1324 (21.3) | 304 (4.9) (84.9) | 1.0 (−) | 1419 (22.8) (80.8) | 1.0 (−) |
| Brazil | 546 (7.3) | 403 (73.8) | 24 (4.4) | 8 (1.5) (2.2) | 0.21 (0.1–0.42)b | 111 (20.3) (6.3) | 0.61 (0.49–0.77)b |
| Canada | 420 (5.6) | 119 (28.3) | 87 (20.7) | 15 (3.6) (4.2) | 1.31 (0.76–2.27) | 199 (47.4) (11.3) | 3.73 (2.95–4.72)b |
| Spain | 275 (3.7) | 182 (66.2) | 34 (12.4) | 31 (11.3) (8.7) | 1.77 ( 1.19–2.64)b | 28 (10.2) (1.6) | 0.34 (0.23–0.51)b |
| Racee | |||||||
| White | 3938 (52.8) | 2418 (61.4) | 545 (13.8) | 177 (4.5) (49.4) | 1.0 (−) | 798 (20.3) (45.4) | 1.0 (−) |
| American Indian/Alaska Native | 33 (0.4) | 14 (42.4) | 6 (18.2) | 6 (18.2) (1.7) | 5.86 (2.22– 15.43)b | 7 (21.2) (0.4) | 1.52 (0.61–3.77) |
| Asian/Pacific Islander | 1357 (18.2) | 443 (32.6) | 503 (37.1) | 55 (4.1) ( 15.4) | 1.70 ( 1.23–2.33)b | 356 (26.2) (20.3) | 2.44 (2.07–2.86)b |
| Black | 1660 (22.3) | 878 (52.9) | 280 (16.9) | 87 (5.2) (24.3) | 1.35 ( 1.04– 1.77)b | 415 (25.0) (23.6) | 1.43 (1.24–1,65)b |
| Other | 124 (1.7) | 98 (79.0) | 14 (11.3) | 3 (2–4) (0.8) | –(−) | 9 (7.3) (0.5) | –(−) |
| Unknown | 340 (4.6) | 17 (5.0) | 121 (35.6) | 30 (8.8) (8.4) | –(−) | 172 (50.6) (9.8) | –(−) |
| Ethnicityf | |||||||
| Hispanic | 2732 (36.7) | 1648 (60.3) | 368 (13.5) | 130 (4.8) (36.3) | 1.0 (−) | 586 (21.4) (33.4) | 1.o(−) |
| Non-Hispanic | 3602 (48.3) | 1635 (45.4) | 930 (25.8) | 173 (4.8) (48.3) | 1.34 (1.06–l.70)b | 864 (24.0) (49.2) | 1.49 (1.31–1.68)b |
| Non-US/Canadian | 821 (11.0) | 585 (71.3) | 58 (7.1) | 39 (4.8) (10.9) | –(−) | 139 (16.9) (7.9) | –(−) |
| Unknown | 297 (4.0) | –(−) | 113 (38.0) | 16 (5.4) (4.5) | –(−) | 168 (56.6) (9.6) | –(−) |
| Indications for LTBI treatmentg | |||||||
| Contact | 4717 (63.3) | 2602 (55.2) | 710 (15.1) | 195 (4.1) (54.5) | 1.0 (−) | 1210 (25.7) (68.9) | 1.0 (−) |
| Contact and TST converter | 342 (4.6) | 239 (69.9) | 29 (8.5) | 18 (5.3) (5.0) | 1.01 (0.61–1.66) | 56 (16.4) (3.2) | 0.50 (0.37–0.68) |
| TST converter | 1861 (25.0) | 855 (45.9) | 458 (24.6) | 122 (6.6) (34.1) | 1.90 ( 1.5–2.42)b | 426 (22.9) (24.2) | 1.07 (0.94–1.23) |
| Fibrosis | 333 (4.5) | 74 (22.2) | 206 (61.9) | 10 (3.0) (2.8) | 1.80 (0.92–3.55) | 43 (12.9) (2.4) | 1.25 (0.85–1.83) |
| HIV-positive | 150 (2.0) | 80 (53.3) | 42 (28.0) | 12 (8.0) (3.4) | 2.00 ( 1.07–3.74)b | 16 (10.7) (0.9) | 0.43 (0.25–0.74) |
Birthplace: Americas-other (Americas, not Canada or the United States); Cl: confidence interval; fibrosis: fibrosis on chest radiograph; HIV: human immunodeficiency virus; LTBI: latent tuberculosis infection; LTBI treatment indications—contact: contact with infectious tuberculosis case; contact and TST converter: contact with infectious tuberculosis case and TST converter; OR: odds ratio; TST: tuberculin skin test; WHO: World Health Organization.
Age group: “Unknown” (total, n = I; not enrolled, n = I): among those not enrolled and not included in univariate analysis.
logistic regression and Wald chi-square tests were used to generate ORs and 95% CIs, compared not enrolled categories with enrolled. All overall P-values (not shown) for variables were significant except for “Sex: Total”; significant variable categories are indicated with footnoteb.
Birthplace: “Non-WHO Region” (total, n = 3; not enrolled, n = I) and “Unknown” include not reported (total, n = 346; not enrolled, n = 345): not included in univariate analysis.
Screening country: one site only in Canada enrolled (n = 6) and did not provide information about patients who were screened but not enrolled.
Race: “Other” includes multiracial (total, n = 124, not enrolled, n = 26), and “Unknown” includes not reported (total, n = 340; not enrolled, n = 323): not included in univariate analysis.
Ethnicity: for the main PREVENT TB (Sterling et al.3), ethnicity was evaluated only among patients screened in the United States and Canada. “Unknown” includes not reported (total, n = 297; not enrolled, n = 297): not included in univariate analysis.
indications for LTBI treatment: participants who had other combinations of risk factors (n = 49); not shown because of limited numbers.